Baiteng Zhao, Ph.D.
CEO, Chair of the Board
Dr. Zhao brings many years of working experience in both large pharma and small biotech companies. Prior to cofounding ProfoundBio he was responsible for the overall modeling and simulation strategies for the entire development pipeline and supported both preclinical and clinical development of ADC drug candidates. Before joining Seagen in 2009, he worked at Merck (MRL, USA) and supported the clinical pharmacology, drug metabolism, and pharmacokinetics for multiple clinical development programs in multiple therapeutic areas. Dr. Zhao obtained his Ph.D. degree in Pharmaceutics from the University of Texas at Austin and B.S. degree in Biology from Peking University. He completed his post-doctoral training at the Department of Pharmaceutical Sciences, State University of New York at Buffalo. Dr. Zhao has authored ten plus peer-reviewed papers and contributed to one book chapter on ADCs and is an inventor of two ADC patents.
Tae H Han, Ph.D.
Dr. Han joined ProfoundBio with extensive experience in drug development focused on preclinical development, translational medicine, and clinical pharmacology. In his career, Dr. Han supported multiple compound modalities, including small molecules, antibody-drug conjugates (ADCs), and bispecific antibody products, from discovery through commercialization. Dr. Han has extensive experience with ADCs and supported the development of two approved products, ADCETRIS™ and PADCEV™. Dr. Han received his B.S. in Chemical Engineering from the University of Washington, and Ph.D. in Chemical and Biomolecular Engineering from the University of California, Los Angeles where he also trained as a post-doctoral fellow in the School of Medicine, Division of Cardiology.
Xiao Shang, Ph.D.
Dr. Shang has over 20 years of experience in the research and development of small molecule drugs and antibody-drug conjugates (ADCs). Prior to ProfoundBio, Dr. Shang was senior vice president at Shenogen Pharma Group, responsible for the research, development and manufacturing of ADCs, peptide drug conjugate as well as small molecule oncology drugs. At Seattle Genetics (now Seagen), Dr. Shang was a principal scientist and a team leader working on the discovery and optimization of synthetic processes and GMP production of the highly potent drugs and drug-linkers. His experience spans from ADC candidate selection through IND, clinical trials, process validation, BLA approval to commercial production for the world’s first highly efficacious and successful ADC, Adcetris. Prior to Seagen, he worked at Rhone Poulenc, Pathogenesis, and then Chiron as a small molecule drug discovery and process development research scientist. Dr. Shang holds a Ph.D. degree in organic synthesis from the University of Alberta, Canada, and a B.Sc. degree from Peking University, China. Dr. Shang has published 18 peer reviewed scientific papers and received 12 patents in the biotech and pharmaceutical industry, and won numerous awards and recognitions from schools, workplaces and governments.